Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

PURPOSE: The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with relapsed/refractory neuroblastoma in the randomized Children’s Oncology Group ANBL1221 trial. To more accurately assess respo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Mody, Rajen, Yu, Alice L., Naranjo, Arlene, Zhang, Fan F., London, Wendy B., Shulkin, Barry L., Parisi, Marguerite T., Servaes, Sabah-E-Noor, Diccianni, Mitchell B., Hank, Jacquelyn A., Felder, Mildred, Birstler, Jennifer, Sondel, Paul M., Asgharzadeh, Shahab, Glade-Bender, Julia, Katzenstein, Howard, Maris, John M., Park, Julie R., Bagatell, Rochelle
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2020
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325366/
https://ncbi.nlm.nih.gov/pubmed/32343642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00203
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items